These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20937018)

  • 1. Emerging therapeutic targets and agents for glioblastoma therapy - part I.
    Lo HW
    Anticancer Agents Med Chem; 2010 Jul; 10(6):437. PubMed ID: 20937018
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging therapeutic targets and agents for glioblastoma therapy--part II.
    Lo HW
    Anticancer Agents Med Chem; 2010 Sep; 10(7):511. PubMed ID: 21070189
    [No Abstract]   [Full Text] [Related]  

  • 3. STAT3 as a Therapeutic Target for Glioblastoma.
    Liu Y; Li C; Lin J
    Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis Suggests Drug Combos for Glioblastoma.
    Cancer Discov; 2016 Jun; 6(6):OF2. PubMed ID: 27165727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible role for furazolidone in the treatment of glioblastoma multiforme.
    Karamanakos PN
    J BUON; 2013; 18(4):1097. PubMed ID: 24344045
    [No Abstract]   [Full Text] [Related]  

  • 6. SUMOylation in Glioblastoma: A Novel Therapeutic Target.
    Fox BM; Janssen A; Estevez-Ordonez D; Gessler F; Vicario N; Chagoya G; Elsayed G; Sotoudeh H; Stetler W; Friedman GK; Bernstock JD
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30991648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanisms of Treatment Resistance in Glioblastoma.
    Ou A; Yung WKA; Majd N
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SnapShot: glioblastoma multiforme.
    Kotliarova S; Fine HA
    Cancer Cell; 2012 May; 21(5):710-710.e1. PubMed ID: 22624719
    [No Abstract]   [Full Text] [Related]  

  • 9. Histone acetyltransferases as promising therapeutic targets in glioblastoma resistance.
    Pathikonda S; Amirmahani F; Mathew D; Muthukrishnan SD
    Cancer Lett; 2024 Nov; 604():217269. PubMed ID: 39326554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using the molecular classification of glioblastoma to inform personalized treatment.
    Olar A; Aldape KD
    J Pathol; 2014 Jan; 232(2):165-77. PubMed ID: 24114756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy.
    Mattei V; Santilli F; Martellucci S; Delle Monache S; Fabrizi J; Colapietro A; Angelucci A; Festuccia C
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Glioblastoma: Efficacy of Ruthenium-Based Drugs.
    Rasin P; Surendran SS; K S K; Haribabu J; Sreekanth A
    Chem Res Toxicol; 2024 Sep; 37(9):1453-1455. PubMed ID: 39163492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies.
    Balça-Silva J; Matias D; Carmo AD; Sarmento-Ribeiro AB; Lopes MC; Moura-Neto V
    Semin Cancer Biol; 2019 Oct; 58():130-141. PubMed ID: 30266571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy resistance of glioblastoma stem cells.
    Eramo A; Ricci-Vitiani L; Zeuner A; Pallini R; Lotti F; Sette G; Pilozzi E; Larocca LM; Peschle C; De Maria R
    Cell Death Differ; 2006 Jul; 13(7):1238-41. PubMed ID: 16456578
    [No Abstract]   [Full Text] [Related]  

  • 17. Exploring Ubiquitin-specific proteases as therapeutic targets in Glioblastoma.
    Samuel VP; Moglad E; Afzal M; Kazmi I; Alzarea SI; Ali H; Almujri SS; Abida ; Imran M; Gupta G; Chinni SV; Tiwari A
    Pathol Res Pract; 2024 Aug; 260():155443. PubMed ID: 38981348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis.
    Zhu Z; Du S; Du Y; Ren J; Ying G; Yan Z
    J Neurochem; 2018 Jan; 144(1):93-104. PubMed ID: 29105080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Experimenter's Guide to Glioblastoma Invasion Pathways.
    de Gooijer MC; Guillén Navarro M; Bernards R; Wurdinger T; van Tellingen O
    Trends Mol Med; 2018 Sep; 24(9):763-780. PubMed ID: 30072121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein.
    Leweke F; Damian MS; Schindler C; Schachenmayr W
    Pathol Res Pract; 1998; 194(3):149-55. PubMed ID: 9587932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.